Eliquis vs Lovenox
Side-by-side cost comparison based on Medicare Part D data
Eliquis
Apixaban
Manufactured by Bristol-Myers Squibb
Lovenox
Enoxaparin
Manufactured by Sanofi
Lovenox costs 82% less per claim than Eliquis ($94.00 vs $510.00). A generic version of Lovenox is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Eliquis | Lovenox |
|---|---|---|
| Avg Cost Per Claim | $510.00 | $94.00 |
| Total Medicare Spending | $16.6B | $456.0M |
| Total Beneficiaries | 3,850,000 | 580,000 |
| Total Claims | 32,460,000 | 4,860,000 |
| Annual Cost/Patient | $4,300.00 | $786.00 |
| Year-over-Year Change | +14.2% | -14.2% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Bristol-Myers Squibb | Sanofi |
| Condition | Blood Clots | Blood Clots |
| Generic Name | Apixaban | Enoxaparin |
Eliquis vs Lovenox: What the Data Shows
Eliquis (Apixaban) and Lovenox (Enoxaparin) are both used to treat blood clots. Based on Medicare Part D data, Lovenox costs $94.00 per claim, which is 82% less than Eliquis at $510.00 per claim.
Medicare spent $16.6B on Eliquis and $456.0M on Lovenox. In terms of patient reach, Eliquis serves more beneficiaries (3,850,000 vs 580,000).
Year-over-year spending changed +14.2% for Eliquis and -14.2% for Lovenox. Eliquis saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Lovenox is cheaper at $94.00 per claim, compared to $510.00 for Eliquis. That makes Lovenox about 82% less expensive per claim based on Medicare Part D data.
Yes, both Eliquis and Lovenox are used to treat blood clots. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Apixaban and generic Enoxaparin can offer significant cost savings, typically 80-95% less than the brand name.
Medicare Part D spent $16.6B on Eliquis covering 3,850,000 beneficiaries, and $456.0M on Lovenox covering 580,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
Comparing Eliquis and Lovenox on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.